GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
548
c/trialwatch·posted 1 months ago by u/milan_villalobos

[Question] how do you actually verify SURPASS

Stats Cold Box ×3

Slightly embarrassed to be asking this, but: how do you actually verify SURPASS.

Argued for a week about a result and then read the limitations section, which conceded most of my opponent’s point.

On means, which this board treats as targets and which are nothing of the sort.

A reported mean body weight change is the centre of a distribution that in these trials is very wide. Substantial numbers of participants did much better, and substantial numbers did considerably worse while remaining on the drug and in the analysis.

Quoting the mean as an expectation therefore misleads in both directions: it makes ordinary results look like failures and it makes exceptional results look normal. If a paper publishes the distribution — and several do, in the appendix — look at that instead. It is far more informative than the number in the abstract.

Why comparing across trials almost never works, with the specific failure modes.

Different populations: an obesity programme and a diabetes programme enrol different people with different baseline characteristics. Different endpoints: body weight change, glycaemic control and cardiovascular events are not convertible. Different durations: 68 weeks and 72 weeks are not the same, and the curves have not flattened by either.

Different analysis populations: one paper reports intention-to-treat, another emphasises completers. Different support: some trial designs include structured lifestyle contact that no member of this board receives.

Stack those and the "X beats Y" tables that circulate here are comparing five things at once and attributing the difference to the molecule.

Happy to answer the boring questions. Those are usually the ones worth asking.

725 up / 177 down80% upvoted18 commentsid 147sxh14 Jun 2026

18 comments

11 in this archive, depth 4

best — the order this archive was captured in

u/renal_outcomes_rMOD75 points·1 months ago

Added the trial identifier to the title so this thread is findable in two years.

replysharereportpermalink
u/anders_kuusela18 points·1 months ago·edited

Not convinced. Cross-trial comparison between two programmes with different populations and designs is not a comparison.

replysharereportpermalink
u/milan_villalobosOP-7 points·1 months ago

Not convinced.

Agreed. And the interval, not the point estimate, is what the trial actually established.

replysharereportpermalink
u/milan_villalobosOP11 points·1 months ago

Is that intention-to-treat or completers?

replysharereportpermalink
u/cesar_ivaturi7 points·1 months ago

Is that intention-to-treat or completers?

Adding the check nobody runs — the registered protocol is public and takes two minutes to compare.

replysharereportpermalink
u/customs_seizure_sid46 points·1 months ago

A confidence interval is the range of effects compatible with the data. Two trials with overlapping intervals have not disagreed, whatever their point estimates look like next to each other.

replysharereportpermalink
u/line_demir34 points·1 months ago

Quoted a figure here confidently, got asked whether it was ITT, went and checked, and it was not. Learned something.

replysharereportpermalink
u/injection_site_iris30 points·1 months ago·edited

Do you have the publication or the press release?

replysharereportpermalink
u/milan_villalobosOP19 points·1 months ago

SURPASS is the diabetes programme and reports glycaemic endpoints

replysharereportpermalink
[removed]33 points·1 months ago

[removed by moderator]

replysharereportpermalink
u/receipts_or_nothingvetting12 points·1 months ago

Right — trial participants get structured support. Comparing yourself to a trial mean is comparing across two different interventions.

replysharereportpermalink
Permalinked branches
Deep branches get their own page so a single reply chain can be linked and read on its own.
About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.